Hillstream BioPharma, Inc.
HILS · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.00 | -0.01 |
| FCF Yield | -219.38% | -1,146.07% | -2,138.41% | -1,022.57% |
| EV / EBITDA | 0.93 | 0.33 | 0.61 | 1.16 |
| Quality | ||||
| ROIC | -503.91% | 312.60% | -422.92% | -128.10% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.88 | 0.62 | 1.06 | 0.94 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 57.51% | 46.41% | -75.19% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 1.21 | 0.42 | 0.65 | 1.24 |
| Interest Coverage | -300.46 | -300.63 | 184.67 | 1,284.67 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |